In light of this, JNK- and ERK-specific inhibitors, SP600125 and PD98059, were employed, and the results suggest that apatinib exerted an inhibitory effect on the progression of sorafenib-resistant HCC by inhibiting both EMT and the EGFR/JNK/ERK pathway. This evidence concerns the gene MAPK8 and hepatocellular carcinoma.